NPS Pharmaceuticals 8-K 2006
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
July 13, 2006
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
383 Colorow Drive
Salt Lake City, Utah 84108
(Address of principal executive offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
NPS Pharmaceuticals and certain of its officers have been named as defendants in purported shareholder class action lawsuits filed in the United States District Court for the District of Utah. The lawsuits allege that between August 2005 and May 2006, the defendants made false and misleading statements concerning the companys prospects for its proprietary drug, PREOS, in violation of U.S. securities laws. The plaintiff seeks class certification for the lawsuit, compensatory damages in an unspecified amount and unspecified equitable or injunctive relief. The company believes the claims are without merit and will defend against them vigorously.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 13, 2006